関連する実験動画
Updated: Jun 14, 2026

10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
因子XIIa阻害剤 リコンビナントヒューマン・アルバミン インフェスティン-4は,出血に影響を与えることなく,閉塞性動脈血栓形成を廃止します
Ina Hagedorn1, Stefan Schmidbauer, Irina Pleines
1University Clinic, University of Würzburg, 97080 Würzburg, Germany.
Circulation
|March 24, 2010
まとめ
新しい阻害剤であるrHA-Infestin-4は,動物モデルでの病理性血栓形成と不全性脳卒中を効果的に予防します. このXIIa因子阻害剤は,血液静止を損なうことなく強力な抗血栓性保護を提供します.
科学分野:
- バイオケミストリー バイオケミストリー
- 薬理学 薬理学とは
- 血液学 ヘマトロジ
背景:
- 血液の凝固は,静止のために不可欠なプロセスですが,また,心筋梗塞や脳卒中などの血栓性疾患を引き起こす可能性があります.
- 素因子XII (FXII) は,病理性血栓形成において重要な役割を果たしますが,正常な血液静止には不可欠ではありません.
- FXIIは,安全な抗血栓剤戦略の潜在的な治療標的である.
研究 の 目的:
- 病理性血栓症および不血症イベントの予防における新しい因子XIIa阻害剤,rHA-Infestin-4の有効性を調査する.
- rHA-Infestin-4の血静への影響を評価することにより,その安全性を評価する.
主な方法:
- インフェスティン-4の補完DNAは,再結合ヒトアルバミン (rHA) と融合した.
- rHA-Infestin-4の因子XIIa阻害と,ヒト,マウス,ネズミの血における活性化部分性血栓形成時間 (aPTT) に及ぼす影響に関するインビトロ分析.
- マウスとラットにおけるイン・ビボ試験は,出血検査と並行して,血栓形成と血性脳卒中モデルにおける保護を評価するものです.
主要な成果:
- rHA-Infestin-4は,ファクターXIIaの特定の阻害を示し,複数の種でaPTTを延長しました.
- In vivoでは,rHA-Infestin-4はマウスとネズミの動脈血栓形成を完全に防ぐことができました.
- rHA-Infestin-4は,正常な血液静止状態を維持しながら,脳卒中のマウリンモデルで有意な保護を提供しました.
結論:
- rHA-Infestin-4は,ファクターXIIaの強力な阻害剤である.
- この薬剤は,不全性心血管および脳血管イベントに対する強力な保護を提供します.
- rHA-Infestin-4は,血液静止に関する良好な安全性プロファイルを持つ抗血栓治療の有望な治療候補である.
関連する概念動画
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...

